Multi-drug resistance and cancer

Bibliography

• GOTTESMAN MM, LING V: The molecular basis of multi-drug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. (2006) 580:998-1009.
   PubMed Web of Science ®Google Scholar
• MAHADEVAN D, SHIRAHATTI N: Strategies for targeting the multi-drug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr. Cancer Drug Targets (2005) 5:445-455.
   PubMed Web of Science ®Google Scholar
• AMBUDKAR SV, KIMCHI-SARFATY C, SAUNA ZE, GOTTESMAN MM: P-glycoprotein: from genomics to mechanism. Oncogene (2003) 22:7468-7485.
   PubMed Web of Science ®Google Scholar
• BORST P, EVERS R, KOOL M, WIJNHOLDS J: The multi-drug resistance family. Biochim. Biophys. Acta. (1999) 1461:347-357.
   PubMed Web of Science ®Google Scholar
• RAO VV, DAHLHEIMER JL, BARDGETT ME et al.: Choroid plexus epithelial expression of MDR1 P-glycoprotein and multi-drug resistance-associated protein contribute to the blood–cerebrospinal fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA (1999) 96:3900-3905.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM, PASTAN I: Biochemistry of multi-drug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. (1993) 62:385-427.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM, FOJO T, BATES SE: Multi-drug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2:48-58.
   PubMed Web of Science ®Google Scholar
• RAMAKRISHNAN P: The role of P-glycoprotein in the blood–brain barrier. Einstein Quart. J. Biol. Med. (2003) 19:160-165.
   Google Scholar
• BORST P, SCHINKEL AH: Genetic dissection of the function of the mammalian P-glycoproteins. Trends Genet. (1997) 13:217-222.
   PubMedGoogle Scholar
• HIGGINS CF, GOTTESMAN MM: Is the multidrug transporter a flippase? Trends Biochem. Sci. (1992) 17:18-21.
   PubMed Web of Science ®Google Scholar
• JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. (1976) 455:152-162.
   PubMed Web of Science ®Google Scholar
• AMBUDKAR SV, DEY S, HRYCYNA CA, RAMACHANDRA M, PASTAN I, GOTTESMAN MM: Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. (1999) 39:361-398.
   PubMed Web of Science ®Google Scholar
• DEY S, RAMACHANDRA M, PASTAN I, GOTTESMAN MM, AMBUDKAR SV: Evidence for two non-identical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA (1997) 94:10594-10599.
   PubMed Web of Science ®Google Scholar
• COLE SP, BHARDWAJ G, GERLACH JH et al.: Overexpression of a transporter gene in a multi-drug resistant human lung cancer cell line. Science (1992) 258:1650-1654.
   PubMed Web of Science ®Google Scholar
• KRUH GD, BELINSKY MG: The MRP family of drug efflux pumps. Oncogene (2003) 22:7537-7552.
   PubMed Web of Science ®Google Scholar
• FLENS MJ, ZAMAN GJR, VAN DER VALK P et al.: Tissue distribution of the multi-drug resistance protein. Am. J. Pathol. (1996) 148:1237-1247.
   PubMed Web of Science ®Google Scholar
• FLENS MJ, IZQUIERDO MI, SCHEFFER GL et al.: Immunochemical detection of the multi-drug resistance-associated protein (MRP) in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res. (1994) 54:4557-4563.
   PubMed Web of Science ®Google Scholar
• COLE SP, SPARKS KE, FRASER K et al.: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. (1994) 54:5902-5910.
   PubMed Web of Science ®Google Scholar
• CHEN ZS, FURUKAWA T, SUMIZAWA T et al.: ATP-dependent efflux of CPT-11 and SN-38 by the multi-drug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol. (1999) 55:921-928.
   PubMed Web of Science ®Google Scholar
• BURGER H, FOEKENS JA, LOOK MP et al.: RNA expression of breast cancer resistance protein, lung resistance-related protein, multi-drug resistance-associated proteins 1 and 2, and multi-drug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. (2003) 9:827-836.
   PubMed Web of Science ®Google Scholar
• JEDLITSCHKY G, LEIER I, BUCHHOLZ U, BARNOUIN K, KURZ G, KEPPLER D: Transport of glutathione, glucuronate, and sulphate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. (1996) 56:988-994.
   PubMed Web of Science ®Google Scholar
• DOYLE LA, YANG W, ABRUZZO LV et al.: A multi-drug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:15665-15670.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS R, SCHRIML LM, HUTCHINSON A, ROMANO-SPICA V, DEAN M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multi-drug resistance. Cancer Res. (1998) 58:5337-5339.
   PubMed Web of Science ®Google Scholar
• MIYAKE K, MICKLEY L, LITMAN T et al.: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone- resistant cells: demonstration of homology to ABC transporter genes. Cancer Res. (1999) 59:8-13.
   PubMed Web of Science ®Google Scholar
• BAILEY-DELL KJ, HASSEL B, DOYLE LA, ROSS DD: Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta. (2001) 1520:234-241.
   PubMed Web of Science ®Google Scholar
• DOYLE LA, ROSS DD: Multi-drug resistance-mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 22:7340-7358.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN L, GALSKI H, FOJO A et al.: Expression of a multi-drug resistance gene in human cancers. J. Natl. Cancer Inst. (1989) 81:116-124.
   PubMed Web of Science ®Google Scholar
• ATALAY C, DELILOGLU GURHAN I, IRKKAN C, GUNDUZ U: Multi-drug resistance in locally advanced breast cancer. Tumour Biol. (2006) 27:309-318.
   PubMed Web of Science ®Google Scholar
• NOOTER K, WESTERMAN AM, FLENS MJ et al.: Expression of the multi-drug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. (1995) 1:1301-1310.
   PubMed Web of Science ®Google Scholar
• STEINBACH D, SELL W, VOIGT A, HERMANN J, ZINTL F, SAUERBERY A: BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (2002) 16:1443-1447.
   PubMed Web of Science ®Google Scholar
• SAUERBERY A, SELL W, STEINBACH D, VOIGT A, HERMANN J, ZINTL F: Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukemia. Br. J. Haemotol. (2002) 118:147-150.
   PubMedGoogle Scholar
• DIESTRA JE, SCHEFFER GL, CATALA II et al.: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin embedded material. J. Pathol. (2002) 198:213-219.
   PubMed Web of Science ®Google Scholar
• KANZAKI A, TOI M, NAKAYAMA K et al.: Expression of multi-drug resistance- related transporters in human breast carcinoma. Jpn J. Cancer Res. (2001) 92:452-458.
   PubMedGoogle Scholar
• FANEYTE IF, KRISTEL PM, MALIEPAARD M et al.: Expression of the breast cancer resistance protein in breast cancer. Clin. Cancer Res. (2002) 8:1068-1074.
   PubMed Web of Science ®Google Scholar
• TAN B, PIWNICA-WORMS D, RATNER L: Multi-drug resistance transporters and modulation. Curr. Opin. Oncol. (2000) 12:450-458.
   PubMed Web of Science ®Google Scholar
• TSURUO T, IIDA H, TSUKAGOSHI S, SAKURAI Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. (1981) 41:1967-1972.
   PubMed Web of Science ®Google Scholar
• FUTSCHER BW, FOLEY NE, GLEASON-GUZMAN MC, MELTZER PS, SULLIVAN DM, DALTON WS: Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int. J. Cancer (1996) 66:520-525.
   PubMed Web of Science ®Google Scholar
• FORD J: Experimental reversal of P-glycoprotein-mediated multi-drug resistance by pharmacological chemosensitizers. Eur. J. Cancer (1996) 32:991-1001.
   Google Scholar
• CHOUDHURI S, KLAASEN CD: Structure, function, expression, genomic organization and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. (2006) 25:231-259.
   PubMed Web of Science ®Google Scholar
• MILLER TP, GROGAN TM, DALTON WS, SPIER CM, SCHEPER RJ, SALMON SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. (1991) 9:17-24.
   PubMed Web of Science ®Google Scholar
• LIST AF, KOPECKY KJ, WILLMAN CL et al.: Benefit of cyclosporin modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 98:3212-3220.
   PubMed Web of Science ®Google Scholar
• BELPOMME D, GAUTHIER S, PUJADE-LAURAINE E et al.: Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. (2000) 11:1471-1476.
   PubMed Web of Science ®Google Scholar
• MILLWARD MJ, CANTWELL BM, MUNRO NC, ROBINSON A, CORRIS PA, HARRIS AL: Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomized study. Br. J. Cancer (1993) 67:1031-1035.
   PubMed Web of Science ®Google Scholar
• CARLSON RW, O’NEILL AM, GOLDSTEIN LJ et al.: A pilot Phase II trial of valspodar modulation of multi-drug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. (2006) 24:677-681.
   PubMed Web of Science ®Google Scholar
• FRIEDENBERG WR, RUE M, BLOOD EA et al.: Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer (2006) 106:830-838.
   PubMed Web of Science ®Google Scholar
• BAER MR, GEORGE SL, DODGE RK et al.: Phase III study of the multi-drug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood (2002) 100:1224-1232.
   PubMed Web of Science ®Google Scholar
• FRACASSO PM, BRADY MF, MOORE DH et al.: Phase II study of paclitaxel and valspodar (PSC-833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. (2001) 19:2975-2982.
   PubMed Web of Science ®Google Scholar
• NARASAKI F, OKA M, FUKUDA M et al.: A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multi-drug resistance-associated protein (MRP) gene. Cancer Chemother. Pharmacol. (1997) 40:425-432.
   PubMedGoogle Scholar
• ROBERT J, JARRY C: Multi-drug resistance reversal agents. J. Med. Chem. (2003) 46:4805-4817.
   PubMed Web of Science ®Google Scholar
• HYAFIL F, VERGELY C, DU VIGNAUD P, GRAND-PERRET T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. (1993) 53:4595-4602.
   PubMed Web of Science ®Google Scholar
• DANTZIG AH, SHEPARD RL, CAO J et al.: Reversal of P-glycoprotein-mediated multi-drug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. (1996) 56:4171-4179.
   PubMed Web of Science ®Google Scholar
• STARLING JJ, SHEPARD RL, CAO J et al.: Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv. Enzyme Regul. (1997) 37:335-347.
   PubMedGoogle Scholar
• DANTZIG AH, DE ALWIS DP, BURGESS M: Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. (2003) 55:103-150.
   Google Scholar
• SHEPARD RL, CAO J, STARLING JJ, DANTZIG AH: Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int. J. Cancer (2003) 103:121-125.
   PubMed Web of Science ®Google Scholar
• MISTRY P, STEWART AJ, DANGERFIELD W et al.: In vitro and in vivo reversal of P-glycoprotein-mediated multi-drug resistance by a novel potent modulator, XR9576. Cancer Res. (2001) 61:749-758.
   PubMed Web of Science ®Google Scholar
• PUSTZAI L, WAGNER P, IBRAHIM N et al.: Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 104:682-691.
   PubMedGoogle Scholar
• GANDHI L, HARDING MW, NEUBAUER M et al.: A Phase II study of safety and efficacy of the multi-drug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer (2007) 109:924-932.
   PubMed Web of Science ®Google Scholar
• SEIDEN MV, SWENERTON KD, MATULONIS U et al.: A Phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. (2002) 86:302-310.
   PubMed Web of Science ®Google Scholar
• TOPPMEYER D, SEIDMAN AD, POLLAK M et al.: Safety and efficacy of the multi-drug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. (2002) 8:670-678.
   PubMed Web of Science ®Google Scholar
• BRAMWELL VH, MORRIS D, ERNST DS et al.: Safety and efficacy of the multi-drug resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res. (2002) 8:383-393.
   PubMedGoogle Scholar
• PLANTIG AS. SONNEVELD P, VAN DER GAAST A et al.: A Phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2005) 55:91-99.
   PubMedGoogle Scholar
• SANDLER A, GORDON M, DE ALWIS DP et al.: A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res. (2004) 10:3265-3272.
   PubMed Web of Science ®Google Scholar
• RUBIN EH, DE ALWIS DP, POULIQUEN I et al.: A Phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin. Cancer Res. (2002) 8:3710-3717.
   PubMed Web of Science ®Google Scholar
• SAEKI T, NOMIZU T, TOI M et al.: Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol. (2007) 25:411-417.
   PubMed Web of Science ®Google Scholar
• BOUMENDJEL A, BAUBICHON-CORTAY H, TROMPIER D, PERROTTON T, DI PIETRO A: Anticancer multi-drug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. (2005) 4:453-472.
   Google Scholar
• HOOIJBERG JH, BROXTERMAN HJ, SCHEFFER GL et al.: Potent interaction of flavopiridol with MRP1. Br. J. Cancer (1999) 81:269-276.
   PubMed Web of Science ®Google Scholar
• WANG S, FOLKES A, CHUCKOWREE I et al.: Studies on pyrrolopyrimidines as selective inhibitors of multi-drug resistance- associated protein in multi-drug resistance. J. Med. Chem. (2004) 47:1329-1338.
   PubMed Web of Science ®Google Scholar
• LOO TW, CLARKE DM: Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl Cancer Inst. (2000) 92:898-902.
   PubMed Web of Science ®Google Scholar
• SAUNA ZE, PENG XH, NANDIGAMA K, TEKLE S, AMBUDKAR SV: The molecular basis of the action of disulfiram as a modulator of the multi-drug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol. (2004) 65:675-684.
   PubMed Web of Science ®Google Scholar
• DE BRUIN M, MIYAKE K, LITMAN T, ROBEY R, BATES SE: Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. (1999) 146:117-126.
   PubMed Web of Science ®Google Scholar
• CHEARWAE W, WU CP, CHU HY, LEE TR, AMBUDKAR SV, LIMTRAKUL P: Curcuminoids purified from turmeric powder modulate the function of human multi-drug resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol. (2006) 57:376-388.
   PubMed Web of Science ®Google Scholar
• RABINDRAN SK, ROSS DD, DOYLE LA, YANG W, GREENBERGER LM: Fumitremorgin C reverses multi-drug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. (2000) 60:47-50.
   PubMed Web of Science ®Google Scholar
• ALLEN JD, VAN LOEVEZIJN A, LAKHAI JM et al.: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. (2002) 1:417-425.
   PubMed Web of Science ®Google Scholar
• WOEHLECKE H, OSADA H, HERRMANN A, LAGE H: Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer (2003) 107:721-728.
   PubMed Web of Science ®Google Scholar
• GOODIN S, KANE MP, RUBIN EH: Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. (2004) 22:2015-2025.
   PubMed Web of Science ®Google Scholar
• ALTMANN KH, WARTMANN M, O’REILLY T: Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta. (2000) 1470:M79-M91.
   PubMed Web of Science ®Google Scholar
• LUDWIG JA, SZAKACS G, MARTIN SE et al.: Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multi-drug resistance in cancer. Cancer Res. (2006) 66:4808-4815.
   PubMed Web of Science ®Google Scholar
• FORD JM, YANG JM, HAIT WN: P-glycoprotein-mediated multi-drug resistance: experimental and clinical strategies for its reversal. Cancer Treat. Res. (1996) 87:3-38.
   PubMedGoogle Scholar
• GAN HZ, ZHANG GZ, ZHAO JS et al.: Reversal of MDR1 gene-dependent multi-drug resistance using short hairpin RNA expression vectors. Chin. Med. J. (2005) 118:893-902.
   PubMedGoogle Scholar
• YANG JM, VASSIL AD, HAIT WN: Activation of phospholipase C induces the expression of the multi-drug resistance (MDR1) gene through the Raf-MAPK pathway. Mol. Pharmacol. (2001) 60:674-680.
   PubMed Web of Science ®Google Scholar
• WU H, HAIT WN, YANG JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. (2003) 63:1515-1519.
   PubMed Web of Science ®Google Scholar
• EE PL, HE X, ROSS DD, BECK WT: Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol. Cancer Ther. (2004) 3:1577-1583.
   PubMed Web of Science ®Google Scholar
• PENG Z, XIAO Z, WANG Y et al.: Reversal of P-glycoprotein-mediated multi-drug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther. (2004) 11:707-712.
   PubMed Web of Science ®Google Scholar
• KANG H, FISHER MH, XU D et al.: Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res. (2004) 32:4411-4419.
   PubMedGoogle Scholar
• NAGATA J, KIJIMA H, HATANAKA H et al.: Reversal of drug resistance using hammerhead ribozymes against multi-drug resistance-associated protein and multi-drug resistance 1 gene. Int. J. Oncol. (2002) 21:1021-1026.
   PubMed Web of Science ®Google Scholar
• OSADA H, TOKUNAGA T, ABE Y et al.: Reversal of drug resistance mediated by hammerhead ribozyme against multi-drug resistance-associated protein 1 in a human glioma cell line. Int. J. Oncol. (2003) 22:823-827.
   PubMed Web of Science ®Google Scholar
• BURGER AM, SETH AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer (2004) 40:2217-2229.
   PubMed Web of Science ®Google Scholar